Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts.

The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers.

Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Data Science in the Food Industry.

Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.

Not so sweet and simple: impacts of SARS-CoV-2 on the β cell.

DECRYPT trial: study protocol for a phase II randomised controlled trial of cognitive therapy for post-traumatic stress disorder (PTSD) in youth exposed to multiple traumatic stressors.

100 years of insulin: celebrating the past, present and future of diabetes therapy.

Defining important canine zoonotic pathogens within the Prairie Provinces of Canada.

Altered β-Cell Prohormone Processing and Secretion in Type 1 Diabetes.

Clinical trial enrollment at a rural satellite hospital during COVID-19 pandemic.

Index60 as an additional diagnostic criterion for type 1 diabetes.

Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.

The neurotransmitter receptor Gabbr1 regulates proliferation and function of hematopoietic stem and progenitor cells.